

## **Critical Complications of COVID-19: A systematic Review and Meta-Analysis study**

Kimia Vakili<sup>1#</sup> Mobina Fathi<sup>1#</sup>, Fatemeh Sayehmiri<sup>2</sup>, Ashraf Mohamadxhani<sup>3</sup>, Mohammadreza Hajiesmaeili<sup>4</sup>,  
Mostafa Rezaei-Tavirani<sup>5</sup>, Aiyoub Pezeshgi<sup>6</sup>

1. Student research committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2. Student research committee, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3. Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
4. Anesthesiology Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5. Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6. Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

# These authors contributed equally to the manuscript.

### **Corresponding Authors:**

#### **Mohammadreza Hajiesmaeili MD**

Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran  
P.O. Box: 1333635445  
Tel: +98-2151025343  
Fax: +98-2155424040  
E-mail: [mrhajiesmaeili@sbmu.ac.ir](mailto:mrhajiesmaeili@sbmu.ac.ir)

#### **Mostafa Rezaei-Tavirani PhD**

Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
Tel/Fax: +98 21-22439847  
E-mail: Tavirany@yahoo.com  
Email: [tavirany@yahoo.com](mailto:tavirany@yahoo.com)

Running title: Critical Complications of COVID-19

## Abstract

**Background:** Coronavirus disease 2019 (COVID-19) is a novel coronavirus infection that has spread worldwide in a short period and caused a pandemic. The goal of this meta-analysis is to evaluate the prevalence of most common symptoms and complications of COVID-19.

**Methods:** All related studies assessing the clinical complications of COVID-19 have been identified through web search databases (PubMed and Scopus). Relevant data were extracted from these studies and analyzed by stata (ver 14) random-effects model. The heterogeneity of studies were assessed by  $I^2$  index. The publication bias was examined by Funnel plots and Egger's test.

**Results:** 30 studies were in our meta-analysis including 6 389 infected patients. The prevalence of most common symptoms were: fever 84.30% (95% CI: 77.13-90.37;  $I^2=97.74\%$ ), cough 63.01% (95% CI: 57.63-68.23;  $I^2=93.73\%$ ), dyspnea 37.16% (95% CI: 27.31-47.57%;  $I^2=98.32\%$ ), fatigue 34.22% (95% CI: 26.29-42.62;  $I^2=97.29\%$ ) and diarrhea 11.47 % (95% CI: 6.96-16.87;  $I^2=95.58\%$ ), respectively. The most prevalent complications were acute respiratory distress syndrome (ARDS) 33.15% (95% CI: 23.35-43.73;  $I^2=98.56\%$ ), acute cardiac injury 13.77% (95% CI: 9.66-18.45;  $I^2=91.36\%$ ), arrhythmia 16.64% (95% CI: 9.34-25.5;  $I^2=92.29\%$ ), heart failure 11.50% (95% CI: 3.45-22.83;  $I^2=89.48\%$ ), and acute kidney injury (AKI) 8.40 % (95% CI: 5.15-12.31;  $I^2=95.22\%$ ), respectively. According to our analysis, mortality rate of COVID-19 patients were 12.29% (95% CI: 6.20-19.99;  $I^2=98.29\%$ ).

**Conclusion:** We assessed the prevalence of the main clinical complications of COVID-19 and found that after respiratory complications, cardiac and renal complications are the most common clinical complications of COVID-19.

**Keywords:** COVID-19; ARDS; Acute Cardiac Injury; Acute kidney Injury (AKI)

## Highlights:

- The most prevalent complication among critical cases of COVID-19 is ARDS.
- After pulmonary complications, cardiovascular complications (like arrhythmia, heart failure and acute cardiac injury) are the most important threats for COVID-19 patients.
- Renal complications (like AKI) happen as a result of COVID-19, but they are less prevalent than pulmonary and cardiovascular complications.

## 1. Introduction

Since the first emergence of a cluster of pneumonia cases in Wuhan, China on December 2019, the global attraction has been drawn to this disease. The China Center for Disease Control and Prevention, on 9 January 2020, stated that the cause of this newly emerged disease is a novel virus from coronaviridae family, which has been further named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the disease caused by this virus was called corona virus disease 2019 (COVID-19). Unfortunately, this epidemic was not limited to China; the World Health Organization (WHO), on 11 March 2020, announced COVID-19 outbreak a pandemic (1, 2). According to WHO, until the time that we are writing this (11 May 2020), more than 4 000 000 individuals were diagnosed with COVID-19 and unfortunately about 279 000 of them have died (3). Based on the latest reports, the most common symptoms of COVID-19 are fever, dry cough, fatigue, dyspnea and diarrhea (4).

The main clinical complications of COVID-19 are related to respiratory system, from a simple pneumonia in mild cases to acute respiratory distress syndrome (ARDS) and shock in severe patients. The angiotensin-converting enzyme 2 (ACE2) is the host cell receptor responsible for the entry of SARS-CoV-2 and the facilitation of infection. Lung, heart, kidney and intestine cells

express ACE2. According to animal models, ACE2 is downregulated in lung injuries (5); therefore, severe lung inflammation due to SARS-CoV-2 infection can lead to dysregulation of the renin-angiotensin system and further development of ARDS.

Furthermore, SARS-CoV-2 is expected to affect all tissues that express ACE2. Therefore, in addition to respiratory manifestations, cardiovascular and renal complications may occur following COVID-19 infection. In practice, growing evidence demonstrates cardiovascular involvement in COVID-19 disease and its negative impact on prognosis (6). There are also many studies which confirm that acute and chronic renal injuries are expected due to the high expression of ACE2 in the renal tubular epithelium (7).

Since these complications are extremely life-threatening, their prevalence in the clinical outcomes of patients can act as a determining factor in the morbidity and mortality rate of the disease. Therefore, this article aims to determine the prevalence of critical complications of patients with COVID-19 by systematically reviewing recent literatures and analyzing related data.

## **2. Method and material:**

### *2.1. Study selection*

To find eligible cross-sectional and case-control studies published on COVID-19 until 1<sup>st</sup> May 2020, we conducted a web search with citations in the PubMed. Two authors conducted the search process independently. Our search queries included: ‘ARDS AND COVID’, ‘((Heart) OR Cardio-) AND COVID’, ‘((Kidney) OR Renal) AND COVID’ and, ‘Complications AND COVID’. On the basis of paper titles, eligible studies were chosen. In addition, the reference lists of all related reviews (narrative and systematic) were searched to find more related articles.

### *2.2. Inclusion and exclusion criteria*

All the studies in which the clinical complications of COVID-19 were analyzed were examined. To be included in the final analysis, screened studies must report data on the prevalence of each clinical complication in COVID-19 patients, including ARDS, acute heart damage, arrhythmia, heart failure and AKI. Only human studies have been included. The exclusion criteria in our search strategy were systematic reviews and meta-analyzes, duplicate publications, non-human studies, lack of sufficient data and non-English publications. Since COVID-19 is a newly emerged disease and the literature related to this disease is still limited, the quality of the included literatures has not been evaluated.

### *2.3. Data extraction*

For all studies, related data including the name of the first author, date of publication, location of publication, sample size, sample age, sample gender, prevalence of symptoms (including: fever, cough, dyspnea, fatigue, and diarrhea), critical complications (including: ARDS, acute cardiac injury, arrhythmia, heart failure, and AKI) and clinical outcomes (mortality rate) were extracted. To avoid conflicting results, the authors extracted data from each study separately and then the results were compared.

### *2.4. Statistical analysis:*

The prevalence of cardiovascular and renal complications was the effect size in this study. Using the binomial distribution, its variance was assessed (with 95% confidence interval). Average weight was applied to combine the prevalence of different studies. The inverse relationship was existed between the study weight and its variance. Q statistics and I<sup>2</sup> index with  $\alpha$  significance level of less than 10% were applied to investigate the heterogeneity. Meta-analysis (random effects model) were applied, when the studies were heterogeneous. For data analysis, STATA software (version 14) was applied. The Metaprop (meta-analysis for proportion) command was applied in STATA and when p was close to 0 or 1. In order to stabilize the variances, we applied Freeman-Tukey Double Arcsine Transformation (8). In metaprop two variables in the format such that p =

n/N are required to be declared. This study was carried out under the approval of ethics committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1399.083).

### **3. Result**

#### *3.1. Study Selection*

For analysis, we used PRISMA checklist (9). Initially, 137 studies were identified through database searches, and 44 additional studies through other sources. Of these 181 studies, 61 of them were excluded due to duplication. After screening the abstracts, other 55 articles were excluded too. Therefore, the full-text of 85 remaining were evaluated and 28 other studies were excluded for some reasons (Lack of enough information). After careful review of these selected studies, 30 published articles between February 2020 and April 2020 were included for the further analysis (Fig. 1, Table 1).

#### *3.2. Demographic Characteristics of included study*

Pooling all extracted data together, the total number of COVID-19 positive patients was 6 389 including 1402 patients with ARDS, 494 patients with acute cardiac injury and 418 patients with AKI. Selected studies have been conducted primarily in China except 1 in the United States. According to the average calculated from the articles reporting the median age of subjects, the mean age of patients were 57.64 and 45.29%, (95% CI: 42.61% to 47.99%;  $I^2=74.56\%$ ) of the patients were female.

#### *3.3. Clinical Manifestations*

Our meta-analysis revealed that the most common symptoms of COVID-19 were fever 84.30% (95% CI: 77.13-90.37;  $I^2=97.74\%$ ), cough 63.01% (95% CI: 57.63-68.23;  $I^2=93.73\%$ ), dyspnea 37.16% (95% CI: 27.31-47.57%;  $I^2=98.32\%$ ), fatigue 34.22% (95% CI: 26.29-42.62;  $I^2=97.29\%$ ) and diarrhea 11.47% (95% CI: 6.96-16.87;  $I^2=95.58\%$ ), respectively.

#### *3.4. Complications*

Cardiac and renal complications in these patients were also assessed. These most common respiratory complication was ARDS 33.15% (95% CI: 23.35-43.73;  $I^2=98.56\%$ ). The prevalence of arrhythmia, acute cardiac injury and heart failure were 16.64% (95% CI: 9.34-25.5;  $I^2=92.29\%$ ), 15.68% (95% CI: 11.1-20.97;  $I^2=92.45\%$ ), and 11.50% (95% CI: 3.45-22.83;  $I^2=89.48\%$ ), respectively. Unfortunately, few related articles were available for analyzing the prevalence of arrhythmia and heart failure. Furthermore, the primary analysis of AKI showed a prevalence of 9.87% (95% CI: 6.18-14.25;  $I^2=95.64\%$ ) (Table 2).

#### *3.5. Outcomes*

Based on the primary analysis, the mortality rate was 21.70% (95% CI: 12.39-32.70;  $I^2=98.81\%$ ), but after omitting 3 of our included studies conducted only on deceased patients, the total mortality rate was calculated 12.29% (95% CI: 6.20-19.99;  $I^2=98.29\%$ ). We also conducted a subgroup analysis to determine the mortality rate by location. As stated above, our articles were mainly from China with a mortality rate of 11.20 (95% CI: 5.36-18.75;  $I^2=98.34\%$ ) and one of these was from the USA with a mortality rate of 52.38 (95% CI: 29.78-74.29).

#### *3.6. Sensitivity Analysis*

According to the primary analysis, the prevalence of acute cardiac injury was 15.68% (95% CI: 11.1-20.97;  $I^2=92.45\%$ ), but after omitting a part of the data from the Wen-Jun Tu study and conducting sensitivity analysis (omitting outlier data) the prevalence was 13.77% (95% CI: 9.66-18.45;  $I^2=91.36\%$ ) (Figure 2). Apparently, the primary analysis of AKI showed a prevalence of 9.87% (95% CI: 6.18-14.25;  $I^2=95.64\%$ ), and after omitting a part of the data from Wen-Jun Tu study and conducting sensitivity analysis (removed outlier data) the prevalence was 8.40% (95% CI: 5.15-12.31;  $I^2=95.22\%$ ) (Figure 3), respectively.

#### *3.7. Publication Bias*

Figure 4 shows the Beggs funnel plot of studies related to cardiac and renal injury in COVID-19 patients. The interpretation of this plot showed no sign of publication bias in these studies ( $p=0.08$ ); this result implies that reports have been published with both positive and negative results (Figure 4).

#### 4. Discussion

From last days of 2019, a novel coronavirus outbreak has emerged, which has been further named coronavirus disease 2019 (COVID-19), and has been spreading around the world since then (10). The city of Wuhan in China was the first infected area and the starting point of this pandemic (11). COVID-19 is highly transmittable and has a great ability to cause to the cluster of cases (12, 13). To date, no definite treatment has been discovered for COVID-19. Current recommendations regarding this disease include preventive measures to reduce the risk of infection (14, 15). Unfortunately, in severe cases of COVID-19, the disease can lead to acute respiratory distress syndrome (ARDS), which is one of the deadliest complications of COVID-19 and can contribute to death. According to Tian et al (16), the prevalence of severe and mild outcomes were 18% of severe cases, while other 82% were common cases (including: including mild cases (73.3%), non-pneumonia cases (4.2%) and asymptomatic cases (5.0%), respectively).

Our meta-analysis is conducted on data extracted from 30 published studies. These studies collected data from laboratory-confirmed COVID-19 patients and were mainly conducted in Chinese hospitals. According to previous reports during SARS-CoV and MERS-CoV outbreaks, these corona viruses have been seen to affect males more than females (17, 18). And also regarding COVID-19, Yang et al revealed that males are at greater risk than females (19). Our results also confirm these literatures; SARS-CoV-2 has a higher risk in men (54.72% (95% CI: 52.04-57.39;  $I^2=74.33\%$ )) compared to women (45.29% (95% CI: 42.61-47.99;  $I^2=74.56\%$ )). This difference could be the result of stronger innate immune responses in women (20), more harmful lifestyle habits (such as smoking) in men (21) and also greater exposure to occupational hazards in men (e.g. Hunan wet market in China) (22). According to the age-based analysis, the mean age of subjects were 57.64, which is close to the number reported in previous studies (23). Elderly patients have indeed been shown to be at greater risk of more serious complications and further death, which may be related to higher prevalence of comorbidities between elderlies (24) or their weakened immune system (21).

We also extracted data about most frequent symptoms of COVID-19. According to our analysis, fever 84.30% (95% CI: 77.13-90.37;  $I^2=97.74\%$ ), cough 63.01% (95% CI: 57.63-68.23;  $I^2=93.73\%$ ), dyspnea 37.16% (95% CI: 27.31-47.57%;  $I^2=98.32\%$ ), fatigue 34.22% (95% CI: 26.29-42.62;  $I^2=97.29\%$ ) and diarrhea 11.47% (95% CI: 6.96-16.87;  $I^2=95.58\%$ ) are the most prevalent symptoms of COVID-19, respectively. These result are almost similar to previous reports (19, 23).

As we looked at the included studies, we realized that the most reported complication was ARDS; that its prevalence was 33.15% (95% CI: 23.35-43.73;  $I^2=98.56\%$ ). ARDS occurs as a result of the accumulation of fluids in alveoli, and this fluid prevents the lungs from receiving enough air. The cause of this phenomenon is the leakage of fluid from capillaries into alveoli, due to damage of their walls (25). This high prevalence of ARDS is justifiable due to the large pneumonia caused by this virus. From other non-respiratory outcomes, acute cardiac injury and AKI have been the most reported. Acute myocardial injury and its complications were observed in 9.5% of all terminally ill COVID-19 patients in Italy (until 13 April 2020) (26). According to our analyses, the prevalence of acute cardiac injury was 13.77% (95% CI: 9.66% to 18.45%;  $I^2=91.36\%$ ). This complication has signs and symptoms similar to COVID-19 respiratory complications and may develop at any stage of this disease.

Acute myocardial injuries in patients with COVID-19 include arrhythmias, heart failure, cardiac arrest, acute coronary syndromes, cardiomyopathy, myocarditis, cardiogenic shock, pericarditis and pericardial effusion (27). In our analysis, the prevalence of arrhythmia 16.64% (95% CI: 9.34-25.5;  $I^2=92.29\%$ ) and heart failure 11.50% (95% CI: 3.45-22.83;  $I^2=89.48\%$ ) were assessed as well, but due to insufficiency of number of articles and lack of enough data, they actually may overestimate the real numbers. Symptoms related to acute cardiac injury are dyspnea, severe fatigue, chest pain and palpitation. Markers that can help diagnose an acute myocardial injury are high sensitivity troponin I (hs-cTnI) or T (hs-cTnT) and NT-proBNP. Performing an electrocardiogram (ECG) can also be helpful (ECG changes show myocardial ischaemia). Troponin level also has diagnostic value, as inflammatory responses of heart to severe illness can lead to elevated troponin levels (27). The prevalence of AKI was 8.40% (95% CI: 5.15-12.31;  $I^2=95.22\%$ ). AKI is described as a sudden failure in kidney function, which includes both structural damage (injury) and loss of function (failure). Markers that can help diagnose AKI are serum creatinine (sCr) and/or urine output (UO) (28).

As stated before, the main focus of this study is to determine the most frequent respiratory and non-respiratory complications in COVID-19 patients, which can help find the causes of worst outcomes and death in these patients. On March 3, 2020, the mortality rate of COVID-19 was reported by 3.4% by World Health Organization (WHO) (29). While according to our analysis, the mortality rate was 12.29% (95% CI: 6.20-19.99;  $I^2=98.29\%$ ) (this number was calculated after omitting the studies that included only deceased patients). It should be noted that most of our included articles were conducted on severe cases, so this higher mortality rate is reasonable. We also performed a subgroup analysis to determine the mortality rate based on the location, which the results was 11.20% (95% CI: 5.36-18.75;  $I^2=98.34\%$ ) in China and 52.38% (95% CI: 29.78-74.29) in the USA. These results have also overestimated the mortality rate of patients with COVID-19, both due to the inclusion of predominantly severe cases and the lack of sufficient studies with useful data. Since no systematic review and meta-analysis on the non-respiratory outcomes of COVID-19 have yet been published, we look forward this article having useful results for the medical society.

## **5. Conclusion**

COVID-19 infection has a high morbidity rate especially in elderly patients. These severe patients require supportive medical care, which can place a huge burden on nations. There are several complications that can put patients in critical conditions. The most frequent clinical outcome of COVID-19 is respiratory complications, in particular ARDS. There are also some non-respiratory outcomes in COVID-19 patients. Although these outcomes are less common than respiratory outcomes, they can have fatal effects on patients. Two of the most non-respiratory complications in COVID-19 patients are acute cardiac injury and AKI. Knowing this information gives clinicians a brighter insight to what they are fighting against. Since these data are updating day by day, further evaluation of these clinical outcomes is recommended.

## **6. Acknowledgment**

The authors are grateful to Shahid Beheshti University of Medical Sciences, Tehran, IR Iran for their collaborative efforts.

## **7. Funding**

None.

## **8. Conflict of interest**

None declared


## References

1. WHO. WHO announces COVID-19 outbreak a pandemic 2020 [Available from: <http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>.
2. Kreutz R, Algharably EAE-H, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovascular Research. 2020.
3. WHO. Coronavirus disease (COVID-19) Situation Report – 112 2020 [Available from: [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid-19-sitrep-112.pdf?sfvrsn=813f2669\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200511-covid-19-sitrep-112.pdf?sfvrsn=813f2669_2).
4. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020.
5. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6.
6. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology. 2020.
7. South AM, Diz D, Chappell MC. COVID-19, ACE2 and the cardiovascular consequences. American Physiological Society Rockville, MD; 2020.
8. Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals of Mathematical Statistics. 1950:607-11.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of internal medicine. 2009;151(4):W-65-W-94.
10. Ghebreyesus TA. WHO Director-General’s opening remarks at the media briefing on COVID-19- 11 March 2020. World Health Organization <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. 2020.
11. Li J, Xu G. Lessons from the Experience in Wuhan to Reduce Risk of COVID-19 Infection in Patients Undergoing Long-Term Hemodialysis. Clinical Journal of the American Society of Nephrology. 2020.
12. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.
13. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease. 2019.
14. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
15. Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal. 2020.
16. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. Journal of Infection. 2020.
17. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. The Journal of Immunology. 2017;198(10):4046-53.

18. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2016;49:129-33.
19. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2020.
20. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clinical reviews in allergy & immunology*. 2017:1-14.
21. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *Journal of Infection*. 2020.
22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223):497-506.
23. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel medicine and infectious disease*. 2020:101623.
24. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
25. MayoClinic. ARDS [Available from: <https://www.mayoclinic.org/diseases-conditions/ards/symptoms-causes/syc-20355576>].
26. Sanità ISd. Characteristics of SARS-CoV-2 patients dying in Italy [Available from: [https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019\\_13\\_april\\_2020.pdf](https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_13_april_2020.pdf)].
27. NICE. COVID-19 rapid guideline: acute myocardial injury (NICE guideline [NG171]) [Available from: <https://www.nice.org.uk/guidance/ng171>].
28. Makris K, Spanou L. Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. *Clin Biochem Rev*. 2016;37(2):85-98.
29. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 3 March 2020 [Available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---3-march-2020>].
30. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020.
31. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. *American journal of respiratory and critical care medicine*. 2020(ja).
32. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. *Journal of Infection*. 2020.
33. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. *International Journal of Infectious Diseases*. 2020.
34. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *Jama*. 2020;323(11):1061-9.
35. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine*. 2020.
36. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA cardiology*. 2020.
37. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Science China Life Sciences*. 2020;63(3):364-74.



38. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of COVID-19 patients. 2020.
39. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *Bmj*. 2020;368.
40. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. *medRxiv*. 2020.
41. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. *American journal of nephrology*. 2020;51(5):343-8.
42. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *Jama*. 2020.
43. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. *The Journals of Gerontology: Series A*. 2020.
44. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China. *medRxiv*. 2020:2020.03.02.20030452.
45. Cao J, Tu W-J, Cheng W, Yu L, Liu Y-K, Hu X, et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. *Clinical Infectious Diseases*. 2020.
46. Hu L, Chen S, Fu Y, Gao Z, Long H, Ren H-w, et al. Risk factors associated with clinical outcomes in 323 COVID-19 patients in Wuhan, China. *Medrxiv*. 2020.
47. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *Journal of Allergy and Clinical Immunology*. 2020.
48. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. *Clinical Infectious Diseases*. 2020.
49. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. *Journal of medical virology*. 2020.
50. Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. *International Journal of Cardiology*. 2020.
51. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, et al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. *Resuscitation*. 2020.
52. Tu W-J, Cao J, Yu L, Hu X, Liu Q. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. *Intensive care medicine*. 2020:1-4.
53. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. *Journal of Medical Virology*. 2020.
54. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients. *Polish archives of internal medicine*. 2020.



**Fig 1.** Study flow diagram.


**Table 1.** Baseline characteristics of studies included in this meta-analysis.

Study (ref)	Place	Patients (No.)			Age (Median)	Symptoms (P.)					Complications (P.)			Mortality (%)
		All	Male	Female		Fever	Cough	Fatigue	Diarrhea	Dyspnea	Acute Cardiac Injury	AKI	ARDS	
Fei Zhou et al. <sup>(30)</sup>	China	191	119	72	56	94	79	23	5	29	17	15	54	28
Yingzhen Du et al. <sup>(31)</sup>	China	85	62	23		92	22	59	19	59	5		47	
Lang Wang et al. <sup>(32)</sup>	China	339	166	173	69	92	53	40	13	41	21	8	21	19
Xun Li et al. <sup>(33)</sup>	China	25	10	15	73					92			92	100
Nanshan Chen et al. <sup>(14)</sup>	China	99	67	32		83	82	11	2	31		3	17	11
Dawei Wang et al. <sup>(34)</sup>	China	138	75	63		99	59	70	10	31	7	4	20	4
Wei-jie Guan et al. <sup>(4)</sup>	China	1099	637	459	47	44	68	38	4	19		0.5	3	1
Xiaobo Yang et al. <sup>(35)</sup>	China	52	35	17		98	77	12		64		30	67	62
Tao Guo et al. <sup>(36)</sup>	China	187	91	96								15	25	23
Yingxia Liu et al. <sup>(37)</sup>	China	12	8	4		83	92	33	17				50	
Wei Liu et al. <sup>(15)</sup>	China	78	39	39	38		44						26	
Zhen Li et al. <sup>(38)</sup>	China	193	95	98	57	89	69	39	18	36	12	28	28	66
Tao Chen et al. <sup>(39)</sup>	China	274	171	103	62	91	68	50	28	44	44	11	72	41
Bicheng Zhang et al. <sup>(40)</sup>	China	82	54	28	72.5	78	65	46	12	63			100	
Shaobo Shi et al. <sup>(6)</sup>	China	416	205	211	64	80	35	13	4	28		2	23	14
Luwen Wang et al. <sup>(41)</sup>	China	116	67	49	54								10	
Matt Arentz et al. <sup>(42)</sup>	USA	21	11			52	48			76		2		52
TieLong Chen et al. <sup>(43)</sup>	China	203	108	95	54	89	60	8		2				13
Guqin Zhang et al. <sup>(44)</sup>	China	221	108	113	55	91	61	71	11	29	8	5	22	5
Jianlei Cao et al. <sup>(45)</sup>	China	102	53	49	54	81	49	55	11	34	15	20	20	17
Ling Hu et al. <sup>(46)</sup>	China	323	166	157	61	84	51			4	7	5	4	
Chaolin Huang et al. <sup>(22)</sup>	China	41	30	11	49	98	76	44	3	55	12	0.7	29	15
Xiaochen Li et al. <sup>(47)</sup>	China	548	279	269	60	95	76	47	33	57	22	17	38	17
Jiangshan Lian et al. <sup>(48)</sup>	China	136	58	78		85	63	18		13		2	17	0
Jiangshan Lian et al. <sup>(48)</sup>	China	652	349	303		80	65	18		3		2	5	0
Suxin Wan et al. <sup>(49)</sup>	China	135	72	63	47	89	77	33	13	13	7	4	16	0.7
Qing Deng et al. <sup>(50)</sup>	China	112	57	55	65	88	71			56	13			0
Fei Shao et al. <sup>(51)</sup>	China	136	90	46		38	52	49	20	75				0
Wen-Jun Tu et al. <sup>(52)</sup>	China	25	19	6	70						72	76	92	100
Wen-Jun Tu et al. <sup>(52)</sup>	China	149	60	89	51						5	5	5	0
Fan Yang et al. <sup>(53)</sup>	China	91	49	43							34	17	80	100
Qingchun Yao et al. <sup>(54)</sup>	China	108	43	65	52	74	78	26	8	14	7	15	42	11


\*Abbreviations: No=Number; P=prevalence.

**Table 2.** Statistical analysis of reviewed studies


	Number of study	Prevalence (%)	95% CI	I <sup>2</sup> (%)	P Value for heterogeneity
<b>Mortality</b>	22	12.29	(6.20-19.99)	98.29	0.00
Mortality in China	21	11.20	(5.36-18.75)	98.34	0.00
Mortality in USA	1	52.38	(29.78-74.29)		
<b>Gender</b>					
Female	29	45.29	(42.61-47.99)	74.56	0.00
Male	29	54.72	(52.04-57.39)	74.33	0.00
<b>Clinical Manifestations</b>					
Fever	24	84.30	(77.13-90.37)	97.74	0.00
Cough	25	63.01	(57.63-68.23)	93.73	0.00
Dyspnea	23	37.16	(27.31-47.57)	98.32	0.00
Fatigue	21	34.22	(26.29-42.62)	97.29	0.00
Diarrhea	18	11.47	(6.96-16.87)	95.58	0.00
<b>Complications</b>					
<u>Respiratory</u>					
ARDS	27	33.15	(23.35-43.73)	98.56	0.00
<u>Cardiovascular</u>					
Acute Cardiac injury	15	13.77	(9.66-18.45)	91.36	0.00
Arrhythmia	5	16.64	(9.34-25.50)	92.29	0.00
Heart failure	4	11.50	(3.45-22.83)	89.48	0.00
<u>Renal</u>					
AKI	21	8.40	(5.15-12.31)	95.22	0.00



**Fig 2.** Forest Plot of the prevalence of acute cardiac injury in COVID-19 patients. Each square shows effect estimate of individual studies with their 95% CI. Size of squares is proportional to the weight of each study in the meta-analysis. In this plot, studies are shown in the order of publication date and first author's names (based on a random effects model).



**Fig 3.** Forest Plot of the prevalence of acute kidney injury (AKI) in COVID-19 patients. Each square shows effect estimate of individual studies with their 95% CI. Size of squares is proportional to the weight of each study in the meta-analysis. In this plot, studies are shown in the order of publication date and first author's names (based on a random effects model).



**Fig 4.** Begg's funnel plot for publication bias